BARCELONA–(BUSINESS WIRE)–SpliceBio, a clinical-stage genetic medicines company pioneering protein splicing to address diseases caused by mutations in large genes, today announced the appointment of Don Munoz as Chief Financial Officer. Mr. Munoz, wh…
Author: Business Wire
Ikarovec to Advance Pipeline With Exclusive Worldwide Option to VectorBuilder’s Intravitreal Capsid Technology
NORWICH, England & CHICAGO–(BUSINESS WIRE)– #BioTechNews–Ikarovec Ltd, which is developing dual-pathway gene therapies for vision-threatening retinal diseases, and VectorBuilder, a global leader in gene delivery technologies, have entered into an ex…
Bausch + Lomb Partners with Glaucoma Research Foundation and The Glaucoma Foundation to Address a Leading Cause of Irreversible Blindness in the U.S.
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, is launching its fifth annual fundraising challenge with Glaucoma Research Foundat…
Samsung Bioepis beginnt mit der Vermarktung von BYOOVIZ®, einem Biosimilar zu Lucentis (Ranibizumab), in Europa
INCHEON, Korea–(BUSINESS WIRE)–Samsung Bioepis Co., Ltd. gab heute bekannt, dass das Unternehmen mit der direkten Vermarktung von BYOOVIZ®, einem Biosimilar zu Lucentis1 (Ranibizumab), in Europa begonnen hat. Samsung Bioepis hat daran gearbeitet, ein…
Resumen: Samsung Bioepis inicia la comercialización de BYOOVIZ®, biosimilar de Lucentis (ranibizumab) en Europa
INCHEON, Corea–(BUSINESS WIRE)–Samsung Bioepis Co., Ltd. acaba de anunciar que la empresa ha iniciado la comercialización directa de BYOOVIZ®, un biosimilar de Lucentis1 (ranibizumab) en Europa. Samsung Bioepis ha venido trabajando para garantizar un…
Riassunto: Samsung Bioepis avvia la commercializzazione di BYOOVIZ®, biosimilare di Lucentis (ranibizumab), in Europa
INCHEON, Corea–(BUSINESS WIRE)–Samsung Bioepis Co., Ltd. oggi ha annunciato che l’azienda ha avviato la commercializzazione diretta di BYOOVIZ®, un biosimilare di Lucentis1 (ranibizumab), in Europa. Samsung Bioepis si è impegnata per garantire il tra…
Samenvatting: Samsung Bioepis start met de verkoop in Europa van BYOOVIZ®, een biosimilar van Lucentis (ranibizumab)
INCHEON, Korea–(BUSINESS WIRE)–Samsung Bioepis Co., Ltd. heeft vandaag bekendgemaakt dat het bedrijf is begonnen met de directe verkoop van BYOOVIZ®, een biosimilar van Lucentis1 (ranibizumab), in Europa. Samsung Bioepis heeft gewerkt aan een naadloz…
Samsung Bioepis commence la commercialisation de BYOOVIZ®, médicament biosimilaire du Lucentis (ranibizumab), en Europe
INCHEON, Corée–(BUSINESS WIRE)–Samsung Bioepis Co., Ltd. a annoncé aujourd’hui avoir commencé la commercialisation directe de BYOOVIZ®, un médicament biosimilaire du Lucentis1 (ranibizumab), en Europe. Samsung Bioepis s’est efforcé d’assurer un trans…
Bausch + Lomb Completes Refinancing of Outstanding Term B Loans
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “company”), a leading global eye health company dedicated to helping people see better to live better, today announced that it closed the previously a…
Samsung Bioepis Begins Commercialization of BYOOVIZ®, Biosimilar to Lucentis (Ranibizumab), in Europe
INCHEON, Korea–(BUSINESS WIRE)– #biosimilars–Samsung Bioepis announced that the company has begun direct commercialization of BYOOVIZ®, a biosimilar to Lucentis (ranibizumab), in Europe.
7MM Diabetic Macular Edema (DME) Epidemiology Forecast Report 2024-2034: Focus on US, France, Germany, Italy, Spain, UK, and Japan – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Diabetic Macular Edema (DME): Epidemiology Forecast to 2034” report has been added to ResearchAndMarkets.com’s offering. In the 7MM, the diagnosed prevalent cases of DME in diabetes are expected to increase from 2,888,125 …
Alcon to Present at 2026 Annual J.P. Morgan Healthcare Conference
GENEVA–(BUSINESS WIRE)–Alcon (SIX/NYSE: ALC) CEO David Endicott will present at the 2026 J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 a.m. PST. A live webcast of the conference will be available at investor.alcon.com/news-a…
Alcon to Present at 2026 Annual J.P. Morgan Healthcare Conference
GENEVA–(BUSINESS WIRE)–Alcon (SIX/NYSE: ALC) CEO David Endicott will present at the 2026 J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 a.m. PST. A live webcast of the conference will be available at investor.alcon.com/news-a…
17-Year-Old Young Tissue Recipient and 14 Tissue Donors to Share the Healing Power of Cornea and Tissue Donation at the 2026 OneLegacy Donate Life Rose Parade® Float
AZUSA, Calif.–(BUSINESS WIRE)–A 17-year-old high school junior from Pomeroy, WA and 14 cornea and tissue donors will be honored on the 2026 OneLegacy Donate Life float, Treasure Every Moment Together, as part of the iconic Rose Parade® on New Year’s …
L'FDA approva le prime lenti a contatto con profondità di focalizzazione estesa per la presbiopia
BOCA RATON, Fla.–(BUSINESS WIRE)–The Cataltheia Group e la sua controllata, Bruno Vision Care LLC, azienda leader nell’innovazione della salute degli occhi, oggi ha annunciato che la Food and Drug Administration (FDA) statunitense ha approvato la pri…
La FDA autorise la première lentille de contact à profondeur de champ étendue pour la presbytie
BOCA RATON, Floride–(BUSINESS WIRE)–Cataltheia Group et sa filiale américaine Bruno Vision Care LLC, leader dans le domaine de l’innovation en matière de santé oculaire, ont annoncé aujourd’hui que la Food and Drug Administration (FDA) américaine ava…
La FDA autoriza la primera lente de contacto con profundidad de foco extendida para la presbicia
BOCA RATÓN, Florida–(BUSINESS WIRE)–Cataltheia Group y su filial en los Estados Unidos, Bruno Vision Care LLC, líder en innovación en salud ocular, anunciaron hoy que la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA) ha autori…
FDA keurt eerste Extended Depth of Focus-contactlens voor presbyopie goed
BOCA RATON, Fla.–(BUSINESS WIRE)–De Cataltheia Group en Bruno Vision Care LLC, de Amerikaanse dochteronderneming van het bedrijf en leider op gebied van innovatie voor de gezondheid van de ogen, maakten vandaag bekend dat de Amerikaanse FDA (U.S. Foo…
FDA genehmigt erste Kontaktlinse mit erweiterter Tiefenschärfe für Presbyopie
BOCA RATON, Fla.–(BUSINESS WIRE)–Die Cataltheia Group und ihre US-Tochtergesellschaft Bruno Vision Care LLC, ein führendes Unternehmen im Bereich der Augenheilkunde, gaben heute bekannt, dass die US-amerikanische Arzneimittelbehörde FDA (Food and Dru…
FDA Clears First Extended Depth of Focus Contact Lens for Presbyopia
BOCA RATON, Fla.–(BUSINESS WIRE)–The Cataltheia Group and its U.S. subsidiary, Bruno Vision Care LLC, a leader in eye health innovation, today announced that the U.S. Food and Drug Administration (FDA) has cleared the first and only Daily Disposable …